证券代码：300683 证券简称：海特生物 公告编号：2025-047 武汉海特生物制药股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 武汉海特生物制药股份有限公司（以下简称"公司"）拟于 2025 年 11 月 7 日（星期五）14：30 召开 2025 年第一次临时股东大会。现将本次股东大会的相 关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第一次临时股东大会 2、会议召集人：公司董事会 3、会议召开的合法性及合规性：公司第九届董事会第五次会议审议通过了 《关于提请召开 2025 年第一次临时股东大会的议案》，本次股东大会的召开符 合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 11 月 7 日（星期五）14:30。 （2）网络投票时间：2025 年 11 月 7 日。 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 11 月 7 日的交易时间，即 9:15-9:25 ...

第九届监事会第四次会议决议公告 证券代码：300683 证券简称：海特生物 公告编号：2025-044 武汉海特生物制药股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 武汉海特生物制药股份有限公司（以下简称"海特生物"或"公司"）第九 届监事会第四次会议于 2025 年 10 月 22 日在海特科技园公司会议室以现场会议 的方式召开，会议通知于 2025 年 10 月 13 日以通讯方式向全体监事发出。应出 席会议的监事 3 人，实际参加会议的监事 3 人。出席会议的人数超过监事总数的 二分之一，表决有效。会议由监事会主席赵满岐先生主持。本次会议召开的时间、 地点及方式均符合《中华人民共和国公司法》及《公司章程》的有关规定。 二、监事会会议审议情况 经监事审议表决通过了如下决议： （一）审议通过《关于<2025 年第三季度报告>的议案》 监事会认为：公司 2025 年第三季度报告包含的信息公允、全面、真实地反 映了本报告期的财务状况和经营情况。报告内容真实、准确、完整，不存在任何 虚假记载、误导性陈述或重大遗漏。 具体内容 ...

f证券代码：300683 证券简称：海特生物 公告编号：2025-043 武汉海特生物制药股份有限公司 二、董事会会议审议情况 会议经过审议，形成如下决议： （一）审议通过《关于<2025 年第三季度报告>的议案》 董事会认为：公司 2025 年第三季度报告包含的信息公允、全面、真实地反 映了本报告期的财务状况和经营情况。报告内容真实、准确、完整，不存在任何 虚假记载、误导性陈述或重大遗漏。 具体内容详见公司于巨潮资讯网（http://www.cninfo.com.cn）披露的《2025 年第三季度报告》。 本议案提交董事会审议前已经公司董事会审计委员会审议通过。 表决结果：同意 9 票；反对 0 票；弃权 0 票。同意票数占有效表决票的 100%。 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉海特生物制药股份有限公司（以下简称"海特生物"或"公司"）第九届董 事会第五次会议于 2025 年 10 月 22 日 10:00 在海特科技园公司会议室以现场和 通讯相结合的方式召开，会议通知于 2025 ...

海特生物公告，2025年前三季度营业收入4.22亿元，下降6.45%。净利润亏损1.58亿元，下降297.78%。 ...

Core Viewpoint - The company, Haitai Biotech (300683.SZ), announced plans to initiate the preparatory work for issuing H-shares and listing on the Hong Kong Stock Exchange by October 22, 2025, aiming to enhance its global strategy and accelerate overseas business development [1] Group 1: Strategic Intent - The company aims to deepen its global strategy and enhance its international brand image through the issuance of H-shares [1] - The move is intended to create a diversified capital operation platform [1] Group 2: Implementation Details - The company plans to discuss specific implementation steps with intermediary institutions, although details are not yet finalized [1] - The issuance and listing of H-shares will require approval from the board of directors, shareholders, and relevant government and regulatory agencies, indicating significant uncertainty in the process [1]

Financial Performance - Q3 2025 revenue was CNY 146,835,944.28, a decrease of 11.74% year-over-year[4] - Net profit attributable to shareholders was CNY -118,912,745.43, a decline of 600.39% compared to the same period last year[4] - Basic and diluted earnings per share were both CNY -0.9100, reflecting a decrease of 600.00% year-over-year[4] - Total operating revenue for Q3 2025 was CNY 421.90 million, a decrease of 6.1% from CNY 450.99 million in the same period last year[18] - Net profit for the period was a loss of CNY 160.88 million, compared to a loss of CNY 42.20 million in the previous year, indicating a significant increase in losses[19] - The total comprehensive income for the period was -160,882,441.08 CNY, compared to -42,198,124.87 CNY in the previous period[20] - Basic and diluted earnings per share were both -1.21 CNY, a decrease from -0.30 CNY in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,636,981,199.32, down 10.20% from the end of the previous year[4] - The company's total assets decreased to CNY 2.64 billion from CNY 2.94 billion, reflecting a decline of 10.2%[16] - Total liabilities decreased to CNY 393.09 million, down 25.1% from CNY 525.05 million year-on-year[16] - The company's equity attributable to shareholders decreased to CNY 2.23 billion from CNY 2.39 billion, a decline of 7.0%[16] Cash Flow - Cash flow from operating activities showed a net outflow of CNY -76,040,333.68, a significant decline of 374.11%[4] - Cash received from operating activities decreased by 79.23% to CNY 20,121,993.43, attributed to reduced government subsidies[8] - Cash inflows from operating activities totaled 392,529,823.30 CNY, down from 522,280,342.04 CNY in the previous period[21] - Net cash outflow from operating activities was -76,040,333.68 CNY, compared to a net inflow of 27,741,059.46 CNY in the previous period[22] - Cash inflows from investing activities were 909,221,090.88 CNY, a decrease from 1,051,448,272.18 CNY in the previous period[22] - Net cash outflow from investing activities was -151,918,057.34 CNY, compared to -27,744,906.50 CNY in the previous period[22] - Cash inflows from financing activities were 4,000,000.00 CNY, with cash outflows totaling 25,629,159.58 CNY, resulting in a net cash outflow of -21,629,159.58 CNY[22] - The ending cash and cash equivalents balance was 169,534,509.90 CNY, down from 495,003,818.07 CNY in the previous period[22] Investments and Equity - Long-term equity investments increased by 167.17% to CNY 30,944,174.29 due to a change in accounting method[8] - The company reported an asset impairment loss of CNY -105,576,119.74, a staggering increase of 6232.98% year-over-year[8] - Other income decreased by 61.23% to CNY 8,580,423.24, primarily due to the absence of government subsidies recognized in the previous year[8] - The company's cash and cash equivalents decreased to CNY 169,536,509.90 from CNY 419,151,366.14 at the beginning of the period[14] - Trading financial assets increased to CNY 526,217,228.18 from CNY 449,688,893.65, indicating a positive trend in financial investments[14] - Accounts receivable rose to CNY 64,162,099.15 from CNY 62,143,770.60, reflecting an increase in sales on credit[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,437, with no preferred shareholders having restored voting rights[10] - The largest shareholder, Wuhan Sanjiangyuan Investment Development Co., Ltd., holds 19.26% of shares, amounting to 25,209,424 shares, with 5,140,000 shares pledged[10] - The second-largest shareholder, Wuhan Beryl Enterprise Management Co., Ltd., owns 11.30% of shares, totaling 14,790,576 shares[10] Future Plans and Standards - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[19] - The company plans to implement new accounting standards starting from 2025[23] - The company did not undergo an audit for the third quarter financial report[24]

Core Insights - The article discusses the first batch of bio-manufacturing landmark products announced by Hubei Province's Economic and Information Technology Department on October 9, highlighting significant advancements in the bio-manufacturing sector [2]. Group 1: Landmark Products - The first batch of landmark bio-manufacturing products includes: - Dongyang Sunshine: Thiocyanate Erythromycin - Tianji Bioenergy: Ultra-clean biodiesel - Bafeng Pharmaceutical: Amino acid raw materials - Xinhua Yang: Feed enzyme preparations - Guangji Pharmaceutical: High-quality riboflavin - China National Pharmaceutical Group: Inactivated vaccine for Porcine Circovirus Type 2 - Aibotai Bio: Research antibodies - Huisheng Biotechnology: Tylosin tartrate - Hite Bio-pharmaceutical: Injectable Epinephrine - Fuxing Biotechnology: Arachidonic acid (ARA) powder [2][3]. Group 2: Product Categories - The products are categorized into different types: - Scale Replacement Type: Thiocyanate Erythromycin, Ultra-clean biodiesel, Research antibodies, Tylosin tartrate - Key Improvement Type: Amino acid raw materials, Feed enzyme preparations, High-quality riboflavin, Arachidonic acid powder - Major Innovation Type: Inactivated vaccine for Porcine Circovirus Type 2, Injectable Epinephrine [3].

Core Viewpoint - Wuhan XianDao Biomedical Technology Development Co., Ltd. has been established, focusing on various technology platforms including biomass energy resource database and artificial intelligence services [1] Company Summary - The newly established company operates in areas such as biomass energy resource database information systems, artificial intelligence foundational resources and technology platforms, and public resource trading platform technical services [1] - The company is co-owned by Hite Bio (300683) among other stakeholders [1]

Core Viewpoint - The innovative drug concept stocks continue to be active, with significant gains observed in several companies [2] Company Performance - Huabang Health reached the daily limit increase in stock price [2] - Other companies such as Shenlian Bio, Shutaishen, Chenxin Pharmaceutical, Weikang Pharmaceutical, and Hite Bio also experienced upward movement in their stock prices [2]

Core Insights - The recombinant protein concept sector rose by 2.66%, ranking 7th among concept sectors, with 49 stocks increasing in value, including *ST Wanfang, which hit the daily limit, and notable gainers such as Saiseng Pharmaceutical, Kefu Medical, and Rejing Bio, which rose by 9.16%, 7.86%, and 6.96% respectively [1][2] Market Performance - The top-performing concept sectors today included Tonghuashun Fruit Index (+3.40%), Cell Immunotherapy (+3.18%), and PEEK Materials (+3.06%), while the sectors with declines included Military Equipment Restructuring (-1.88%) and Transgenic (-1.07%) [2] - The recombinant protein sector saw a net inflow of 389 million yuan, with 37 stocks receiving net inflows, and 6 stocks attracting over 30 million yuan in net inflows, led by Tonghua Dongbao with 48.94 million yuan [2][3] Fund Flow Analysis - The stocks with the highest net inflow ratios included *ST Wanfang (31.91%), Furuida (13.74%), and North China Pharmaceutical (12.46%) [3] - The top stocks in the recombinant protein sector by net inflow included Tonghua Dongbao (4.55% increase, 48.94 million yuan inflow), Beida Pharmaceutical (-0.77%, 46.41 million yuan inflow), and Hite Bio (5.13%, 35.56 million yuan inflow) [3][4]